Lynch syndrome is a condition that can run in families. It is also known as hereditary non-polyposis colorectal cancer (HNPCC). It is caused by an alteration in a gene called a mismatch repair gene.
Lynch syndrome doesn’t cause any symptoms. But people with Lynch Syndrome have an increased risk of developing bowel cancer, womb cancer and some other cancers.
The NIHR-supported Cancer Prevention Project 3 (CaPP3), is focusing on finding the right dose of aspirin for people with a mismatch repair gene defect, the underlying cause of Lynch syndrome. It follows on from two other cancer prevention studies for Lynch syndrome.
Professor John Burn tells us more about the CaPP3 trial:
Trevor Butler, a patient on the trial, describes his experience of taking part in the NIHR-supported Cancer Prevention Project 3 (CaPP3).
Together, rare cancers account for more than 20% of all cancer diagnoses. This is more than any single common cancer. Unfortunately, the average outcome for patients with a rare cancer is inferior to those with more common cancers. In an attempt to address this issue, the International Rare Cancers Initiative (IRCI) was established early in 2011.
The aim of this initiative is to facilitate the development of international clinical trials for patients with rare cancers in order to boost the progress of new treatments for these patients. The initiative hopes to encourage the use of innovative methodologies to maximise the potential for answering research questions and to identify and overcome barriers to international trials to allow international collaborative trials to run smoothly.Find out more
Find out more about support at lynch-syndrome-uk.org.